Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

191 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bempedoic acid: Everything with a place and purpose.
Westerink J. Westerink J. Eur J Prev Cardiol. 2021 Jul 23;28(8):823-824. doi: 10.1177/2047487320929779. Eur J Prev Cardiol. 2021. PMID: 33611517 Free article. No abstract available.
Combined use of polypill components in patients with type 2 diabetes mellitus.
Janssen VE, Visseren FL, de Boer A, Grobbee DE, Westerink J, van der Graaf Y, Lafeber M; SMART Study Group. Janssen VE, et al. Among authors: westerink j. Eur J Prev Cardiol. 2018 Sep;25(14):1523-1531. doi: 10.1177/2047487318789494. Epub 2018 Jul 23. Eur J Prev Cardiol. 2018. PMID: 30033753
Residual cardiovascular risk reduction guided by lifetime benefit estimation in patients with symptomatic atherosclerotic disease: effectiveness and cost-effectiveness.
Hageman SHJ, Dorresteijn JAN, Bots ML, Asselbergs FW, Westerink J, van der Meulen MP, Mosterd A, Visseren FLJ; UCC-SMART Study Group; Asselbergs FW, Nathoe HM, de Borst GJ, Bots ML, Geerlings MI, Emmelot MH, de Jong PA, Leiner T, Lely AT, van der Kaaij NP, Kappelle LJ, Ruigrok YM, Verhaar MC, Visseren FLJ, Westerink J. Hageman SHJ, et al. Among authors: westerink j. Eur J Prev Cardiol. 2022 Mar 30;29(4):635-644. doi: 10.1093/eurjpc/zwab028. Eur J Prev Cardiol. 2022. PMID: 34009323
Development and validation of a lifetime prediction model for incident type 2 diabetes in patients with established cardiovascular disease: the CVD2DM model.
Helmink MAG, Peters SAE, Westerink J, Harris K, Tillmann T, Woodward M, van Sloten TT, van der Meer MG, Teraa M, Dorresteijn JAN, Ruigrok YM, Visseren FLJ, Hageman SHJ; UCC-SMART study group. Helmink MAG, et al. Among authors: westerink j. Eur J Prev Cardiol. 2024 Apr 8:zwae096. doi: 10.1093/eurjpc/zwae096. Online ahead of print. Eur J Prev Cardiol. 2024. PMID: 38584392
Low high-density lipoprotein cholesterol is not a risk factor for recurrent vascular events in patients with vascular disease on intensive lipid-lowering medication.
van de Woestijne AP, van der Graaf Y, Liem AH, Cramer MJ, Westerink J, Visseren FL; SMART Study Group. van de Woestijne AP, et al. Among authors: westerink j. J Am Coll Cardiol. 2013 Nov 12;62(20):1834-41. doi: 10.1016/j.jacc.2013.04.101. Epub 2013 Aug 21. J Am Coll Cardiol. 2013. PMID: 23948286 Free article.
191 results